版本:
中国

BRIEF-AmpliPhi Biosciences announces topline results from its Phase 1 phage therapy trial conducted in the U.S.

Sept 13 AmpliPhi Biosciences Corp

* AmpliPhi Biosciences announces topline results from its Phase 1 phage therapy trial conducted in the United States

* Safety committee concluded AB-SA01 was well-tolerated by subjects in trial and there were no drug-related serious adverse events

* AmpliPhi expects complete study report will be finalized before end of 2016 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐